SCT510 clinical trials
Also written SCT510.
How each study uses SCT510 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SCT510
- 3
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Sinocelltech Ltd. (2) · First Affiliated Hospital of Zhejiang University (1)
Studies
Open first, then newest update. How each study uses SCT510 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular CarcinomaActive, not recruitingPhase 2/3Sinocelltech Ltd.NCT04560894Written as SCT510
- PK and Safety of SCT510CompletedPhase 1First Affiliated Hospital of Zhejiang UniversityNCT05113511Written as SCT510
- To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung CancerStatus unknownPhase 3Sinocelltech Ltd.NCT03792074Written as SCT510